These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

649 related articles for article (PubMed ID: 2938731)

  • 1. Increased thymidylate synthase in L1210 cells possessing acquired resistance to N10-propargyl-5,8-dideazafolic acid (CB3717): development, characterization, and cross-resistance studies.
    Jackman AL; Alison DL; Calvert AH; Harrap KR
    Cancer Res; 1986 Jun; 46(6):2810-5. PubMed ID: 2938731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of the thymidylate synthase inhibitor 2-desamino-N10-propargyl-5,8-dideazafolic acid and related compounds in murine (L1210) and human (W1L2) systems in vitro and in L1210 in vivo.
    Jackman AL; Taylor GA; O'Connor BM; Bishop JA; Moran RG; Calvert AH
    Cancer Res; 1990 Sep; 50(17):5212-8. PubMed ID: 2386929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study.
    Jackman AL; Taylor GA; Gibson W; Kimbell R; Brown M; Calvert AH; Judson IR; Hughes LR
    Cancer Res; 1991 Oct; 51(20):5579-86. PubMed ID: 1913676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biochemical and biological studies on 2-desamino-2-methylaminopterin, an antifolate the polyglutamates of which are more potent than the monoglutamate against three key enzymes of folate metabolism.
    Rosowsky A; Galivan J; Beardsley GP; Bader H; O'Connor BM; Russello O; Moroson BA; DeYarman MT; Kerwar SS; Freisheim JH
    Cancer Res; 1992 Apr; 52(8):2148-55. PubMed ID: 1313737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human lymphoblastoid cells with acquired resistance to C2-desamino-C2-methyl-N10-propargyl-5,8-dideazafolic acid: a novel folate-based thymidylate synthase inhibitor.
    O'Connor BM; Jackman AL; Crossley PH; Freemantle SE; Lunec J; Calvert AH
    Cancer Res; 1992 Mar; 52(5):1137-43. PubMed ID: 1737372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N10-propargyl-5,8-dideazafolic acid (CB3717): inhibitory effects on human leukemia cell lines resistant to methotrexate or trimetrexate.
    Takemura Y; Ohnuma T
    Mt Sinai J Med; 1992 Oct; 59(5):419-24. PubMed ID: 1435841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The biochemical pharmacology of the thymidylate synthase inhibitor, 2-desamino-2-methyl-N10-propargyl-5,8-dideazafolic acid (ICI 198583).
    Jackman AL; Newell DR; Gibson W; Jodrell DI; Taylor GA; Bishop JA; Hughes LR; Calvert AH
    Biochem Pharmacol; 1991 Oct; 42(10):1885-95. PubMed ID: 1741766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cellular pharmacology and in vivo activity of a new anticancer agent, ZD9331: a water-soluble, nonpolyglutamatable, quinazoline-based inhibitor of thymidylate synthase.
    Jackman AL; Kimbell R; Aherne GW; Brunton L; Jansen G; Stephens TC; Smith MN; Wardleworth JM; Boyle FT
    Clin Cancer Res; 1997 Jun; 3(6):911-21. PubMed ID: 9815766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of thymidylate synthetase and its inhibition by 5-fluorouracil in highly enzyme-overproducing cells resistant to 10-propargyl-5,8-dideazafolate.
    Danenberg KD; Danenberg PV
    Mol Pharmacol; 1989 Aug; 36(2):219-23. PubMed ID: 2528057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thymidylate synthase overproduction and gene amplification in fluorodeoxyuridine-resistant human cells.
    Berger SH; Jenh CH; Johnson LF; Berger FG
    Mol Pharmacol; 1985 Nov; 28(5):461-7. PubMed ID: 2932632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple membrane transport systems for the uptake of folate-based thymidylate synthase inhibitors.
    Jansen G; Schornagel JH; Westerhof GR; Rijksen G; Newell DR; Jackman AL
    Cancer Res; 1990 Dec; 50(23):7544-8. PubMed ID: 2253202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines.
    Jackman AL; Kelland LR; Kimbell R; Brown M; Gibson W; Aherne GW; Hardcastle A; Boyle FT
    Br J Cancer; 1995 May; 71(5):914-24. PubMed ID: 7537518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Membrane transport of natural folates and antifolate compounds in murine L1210 leukemia cells: role of carrier- and receptor-mediated transport systems.
    Westerhof GR; Jansen G; van Emmerik N; Kathmann I; Rijksen G; Jackman AL; Schornagel JH
    Cancer Res; 1991 Oct; 51(20):5507-13. PubMed ID: 1655252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quinazoline antifolates inhibiting thymidylate synthase: computer modelling of the N10 substituent.
    Jones TR; Betteridge RF; Neidle S; Jackman AL; Calvert AH
    Anticancer Drug Des; 1989 Mar; 3(4):243-8. PubMed ID: 2930626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quinazoline antifolate thymidylate synthase inhibitors: gamma-linked L-D, D-D, and D-L dipeptide analogues of 2-desamino-2-methyl-N10-propargyl-5,8-dideazafolic acid (ICI 198583).
    Bavetsias V; Jackman AL; Kimbell R; Gibson W; Boyle FT; Bisset GM
    J Med Chem; 1996 Jan; 39(1):73-85. PubMed ID: 8568829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antifolate drug interactions: enhancement of growth inhibition due to the antipurine 5,10-dideazatetrahydrofolic acid by the lipophilic dihydrofolate reductase inhibitors metoprine and trimetrexate.
    Galivan J; Nimec Z; Rhee M; Boschelli D; Oronsky AL; Kerwar SS
    Cancer Res; 1988 May; 48(9):2421-5. PubMed ID: 2965613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity.
    Westerhof GR; Schornagel JH; Kathmann I; Jackman AL; Rosowsky A; Forsch RA; Hynes JB; Boyle FT; Peters GJ; Pinedo HM
    Mol Pharmacol; 1995 Sep; 48(3):459-71. PubMed ID: 7565626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Formation and retention and biological activity of N10-propargyl-5,8-dideazafolic acid (CB3717) polyglutamates in L1210 cells in vitro.
    Sikora E; Jackman AL; Newell DR; Calvert AH
    Biochem Pharmacol; 1988 Nov; 37(21):4047-54. PubMed ID: 2461200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quinazoline antifolate thymidylate synthase inhibitors: 2'-fluoro-N10-propargyl-5,8-dideazafolic acid and derivatives with modifications in the C2 position.
    Jackman AL; Marsham PR; Thornton TJ; Bishop JA; O'Connor BM; Hughes LR; Calvert AH; Jones TR
    J Med Chem; 1990 Nov; 33(11):3067-71. PubMed ID: 2231607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-based design of lipophilic quinazoline inhibitors of thymidylate synthase.
    Jones TR; Varney MD; Webber SE; Lewis KK; Marzoni GP; Palmer CL; Kathardekar V; Welsh KM; Webber S; Matthews DA; Appelt K; Smith WW; Janson CA; Villafranca JE; Bacquet RJ; Howland EF; Booth CL; Herrmann SM; Ward RW; White J; Moomaw EW; Bartlett CA; Morse CA
    J Med Chem; 1996 Feb; 39(4):904-17. PubMed ID: 8632414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.